1. Executive Summary (Confidence: High)

Bottneuro is pioneering "the new pharma" for neurological diseases, focusing on personalized, non-invasive therapies for Alzheimer's. Founded in 2021 as a spin-off from the University of Basel, the company has developed the Miamind® neurostimulator, a customized 3D-printed helmet that delivers transcranial alternating current stimulation (tACS). Following the successful completion of its first clinical study (Mindstim), which met all safety outcomes and showed a 38% increase in patient attention, Bottneuro launched a Priority Access Program in Switzerland in 2025. The device is registered under MDR as a Custom-Made Device, allowing neurologists to prescribe it for independent, at-home use. With a market opportunity exceeding $500 billion, Bottneuro aims to make Alzheimer’s a manageable condition while restoring patient independence.